Inotuzumab ozogamicin is deliverable in relapsed ALL patients with end-stage renal disease on hemodialysis. Issue 13 (10th November 2022)

Record Type:: Journal Article
Title:: Inotuzumab ozogamicin is deliverable in relapsed ALL patients with end-stage renal disease on hemodialysis. Issue 13 (10th November 2022)
Main Title:: Inotuzumab ozogamicin is deliverable in relapsed ALL patients with end-stage renal disease on hemodialysis
Authors:: Amanam, Idoroenyi
Ngo, Dat
Pullarkat, Vinod
Aldoss, Ibrahim
Abstract:
Is Part Of:: Leukemia & lymphoma. Volume 63:Issue 13(2022)
Journal:: Leukemia & lymphoma
Issue:: Volume 63:Issue 13(2022)
Issue Display:: Volume 63, Issue 13 (2022)
Year:: 2022
Volume:: 63
Issue:: 13
Issue Sort Value:: 2022-0063-0013-0000
Page Start:: 3268
Page End:: 3270
Publication Date:: 2022-11-10
Subjects:: Lymphoid leukemia -- pharmacotherapeutics -- lymphocytes
Leukemia -- Periodicals
Lymphomas -- Periodicals
616.99419
Journal URLs:: http://informahealthcare.com ↗
DOI:: 10.1080/10428194.2022.2113529 ↗
Languages:: English
ISSNs:: 1042-8194
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 5185.251500
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 24705.xml